

Research Article

Comparison of Oxidative Effects of Two Different Administration Form of Oxybutynin in the Potential Target Tissues

Kaan Kaltalioglu ¹, Fatmanur Tugcu-Demiroz,² Fusun Acarturk,² Barbaros Balabanli,³ and Sule Coskun-Cevher³

¹Espiye Vocational School, Giresun University, 28600 Giresun, Turkey

²Pharmaceutical Technology Department, Pharmacy Faculty, Gazi University, 06330 Ankara, Turkey

³Biology Department, Science Faculty, Gazi University, 06500 Ankara, Turkey

Correspondence should be addressed to Kaan Kaltalioglu; kaan.kaltalioglu@gmail.com

Received 9 August 2018; Revised 6 December 2018; Accepted 10 December 2018; Published 24 December 2018

Academic Editor: Matthew Rutman

Copyright © 2018 Kaan Kaltalioglu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oxybutynin is an important anticholinergic agent that prevents uncontrolled contractions in the treatment of overactive bladder (OAB). However, drugs containing oxybutynin have significant side effects such as dry eyes, dry mouth, increased heart rate, constipation, blurred vision, and confusion. In recent years, new delivery methods for this agent are being searched. One of them is vaginal delivery. In this study, we aimed to compare the effects of oxybutynin on oxidative parameters in the potential target tissues of the oral and vaginal delivery. Female New Zealand white rabbits ($n = 12$) were divided into two groups: oral delivery and vaginal delivery. The animals were sacrificed 48 h after administration and nitric oxide (NOx), thiobarbituric acid-reactive substances (TBARs), and glutathione (GSH) levels were determined spectrophotometrically in the aorta, salivary gland, and small intestine tissue samples. Vaginal delivery significantly decreased NOx levels in all tissue samples as compared to oral delivery ($p < 0.05$). Moreover, it reduced TBARs levels in salivary gland and aorta tissue samples ($p < 0.05$). In the light on these findings, it can be said that vaginal delivery may decrease the oxidant-induced side effects of oxybutynin as compared to oral delivery.

1. Introduction

Overactive bladder (OAB) is a syndrome that occurs owing to the spontaneous activity of the detrusor muscle during the filling of bladder and marked by urinary urgency, with/without urge incontinence, usually accompanied by nocturia and frequency [1, 2]. OAB is common in both men and women, and negatively affects the quality of life (QOL) [3]. Recent reports showed that the prevalence of OAB is 35.15% in United States [4], and 20% in Asia (men and women aged ≥ 40 years) [5]. Two main classes of drugs have been used for the treatment of OAB: antimuscarinics (anticholinergics) and $\beta 3$ -adrenoreceptor agonists [6].

The detrusor muscle contractility is generally orchestrated by the parasympathetic nervous system, which acetylcholine (ACh) is the primary neurotransmitter in these actions [7]. Antimuscarinics inhibits the binding of

acetylcholine at M_2 and M_3 muscarinic receptors on bladder smooth muscle to show their effects on OAB. Antimuscarinics has demonstrated efficacy for the treatment of OAB, but they affect the potential target organs or tissues, and they can cause side effects for some people [7]. These side effects such as dry mouth, dry eyes, increased heart rate, constipation, confusion, and blurred vision are related to dose [8].

Oxybutynin, a tertiary amine, is an antimuscarinic agent used widely in the treatment of OAB for many years [6]. Oxybutynin has an antimuscarinic and a direct muscle relaxant effect, as well as local anesthetic actions [9]. Nevertheless, it can cause side effects and is discontinued in over 60% of patients due to adverse effects [10]. Oxybutynin have major side effects include dry eyes, dry mouth, blurred vision, and constipation [2]. Oxybutynin is highly lipophilic molecule to have the ability of penetrate the blood-brain

barrier [6]. *N*-desethyloxybutynin, which is the major metabolite of oxybutynin, may cause systemic side effects. Oxybutynin and *N*-desethyloxybutynin have similar impacts on the detrusor smooth muscle. But, *N*-desethyloxybutynin is more vigorous in the salivary glands (leads to dry mouth) [11].

Vaginal drug delivery systems promise remarkable potential in pharmacy. The major advantages of this route include a considerable surface area, good blood supply, relatively high permeability to many drugs, and the ability to bypass first-pass liver metabolism [2]. Previous works suggested that the vaginal delivery of oxybutynin may have serious advantages over the oral delivery with relation to long duration of action, consistent blood levels, and reduction of side effects [2].

The imbalance between oxidants and antioxidants (called as oxidative stress) is involved in the etiology and/or pathogenesis of a number of disorders [12]. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generate a harmful process that can alter the cell membranes and other structures such as proteins, lipids, proteins, and DNA and trigger various diseases [13, 14]. For instance, Sjögren's Syndrome (SS) is an autoimmune disorder, which leads to dry eye and dry mouth. It has been proposed that oxidative stress plays a role in the pathogenesis of SS [15]. It has also been reported that oxidative stress may cause changes in the structure of the salivary gland and may involve in hypo-salivation [16]. In addition, nitric oxide may also affect saliva secretion [17].

In this study, we compared the effects of oral and vaginal delivery of oxybutynin on some oxidative parameters (NOx, TBARs, and GSH) on the aorta, salivary gland, and small intestine, organs where oxybutynin may cause side effects.

2. Material and Methods

2.1. Drugs and Chemicals. In this study, oxybutynin hydrochloride was obtained from Sigma (USA). Also, Üropan® (Koçak Farma, Turkey) tablet (5 mg oxybutynin) was purchased from markets, and all other chemicals unless until mentioned were of analytical grade.

2.2. Experiment. The protocol of this study was confirmed by the Animal Ethical Committee of Gazi University, Turkey (G.Ü.ET-04.033). Twelve female New Zealand white rabbits weighing 2.5–3.5 kg were housed them in a controlled environment. During the experimental period animals were allowed free access to food and water. They fasted for 24 h before application. The animals were divided randomly into two groups: oral delivery ($n = 6$) and vaginal delivery ($n = 6$). Vaginal solution (containing 10 mg oxybutynin/1.5 mL pH 4.5 phosphate buffer) was administered through the vaginal route with an applicator as a single dose every 48 h. Üropan® tablets (5 mg oxybutynin) were also administered orally through an oral gavage as a single dose every 24 h. After 48 h from administration, the animals were killed with intracardiac blood aspiration under ketamine/xylazine anesthesia (intramuscularly, 75 and 5 mg/kg,

respectively). The aorta, salivary gland, and small intestine tissue samples were collected, frozen and kept in -80° until assay.

2.3. Determination of NOx, TBARs, and GSH. The reactive nitrogen oxide species (NOx) levels were measured spectrophotometrically at 540 nm by Griess reaction. NOx are stable end products of nitric oxide. Sodium nitrite was considered as the standard [18]. Lipid peroxidation was determined spectrophotometrically according to the method detailed before at 535 nm. This method based on the principle that the generation of malondialdehyde (MDA) as an end product of lipid peroxidation, which interacts with thiobarbituric acid producing thiobarbituric acid-reactive substance (TBARs). Tetraethoxypropane solution was considered as a standard for this assay [18]. Levels of glutathione (GSH) were measured spectrophotometrically according to a modified version of the Ellman method at 412 nm. In this method, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) reacts with reduced GSH to form a yellow-colored compound [18].

2.4. Statistical Analysis. All results were defined as the mean \pm standard deviation. One-way ANOVA (with posthoc Tukey test) was used to compare mean differences. Results of $P < 0.05$ were considered to be statistically significant.

3. Results and Discussion

The amounts of the NOx, TBARs, and GSH in the aorta, salivary gland, and small intestine tissue samples are presented in Figure 1. Our results showed that in the vaginal delivery groups, the levels of NOx are significantly lower in all tissue samples (aorta (140.54 ± 4.63 nmol/g tissue), salivary gland (195.99 ± 24.03 nmol/g tissue), and small intestine (154.29 ± 7.37 nmol/g tissue)) as compared to oral delivery groups (228.63 ± 20.13 nmol/g tissue, 343.42 ± 18.33 nmol/g tissue, 198.69 ± 7.23 nmol/g tissue, respectively) ($p < 0.05$) (Figure 1). Nitric oxide, a highly reactive gas molecule, has multiple physiological roles in both intra- and extracellular signal transduction pathways with relations for health and disease [19]. The concentration of NO is critical since it acts as a signaling molecule at low concentrations, although, at high concentrations, NO or RNS can exert toxic effects on the cell; it is damage to proteins, lipids, and DNA and can lead to cell death or tissue injury [14, 20]. Salivation is dependent on cholinergic stimulation via autonomic nerves and intracellular signals in acinar cells [21]. NO and acetylcholine (ACh) function in salivation. NO can stimulate salivary gland cells to secrete fluid, but a prolonged exposure has a detrimental effect on the cells [22]. Konttinen et al. reported that NO is an important factor in altering salivation in SS, which is characterized by dry mouth and dry eye. Nitrite is present at high concentrations in saliva of these patients, and inducible NO synthase (iNOS) expression is elevated in various cells in salivary glands [23]. Also, dry mouth is an important side effect of the administration of oxybutynin. Therefore, the




FIGURE 1: Effects of the oral and vaginal delivery of oxybutynin on NOx (a), TBARs (b), and GSH (c) levels in various tissues. $p < 0.05$ compared to the oral and vaginal delivery group.

preference for vaginal delivery may be beneficial for salivation as it reduces NO concentration.

Otherwise, another side effect of oxybutynin is increased heart rate. NO plays an important role in heart contraction response, heart rate, and regulation of vascular tone [24]. The effects of NO on the heart rate are complex. But, in general, NO has a positive chronotropic effect, and NOS inhibition causes a reduction of heart rate [25]. The different effects of NO might be dependent on its concentration. As shown in Figure 1, the level of NOx in the aorta tissue samples of the vaginal delivery group was significantly lower than oral delivery group ($p < 0.05$).

Constipation is a common side effect that may potentially appear with the use of oxybutynin. Another important function of NO is that it affects the gastrointestinal tract (via relaxation of the enteric smooth muscle). A previous study suggested that NO supports maintain gastric mucosal integrity and has a protective effect [20]. In contrast, in cirrhotic rats, L-NAME (a nonselective inhibitor of NOS) alleviate inhibited-gastrointestinal motility. Wang et al. reported that NO may play an important role in the

inhibition of gastrointestinal motility [26]. In another study, Tomita et al. found that NO has a significant function in the dysmotility detected in the STC patients' colons [27]. Taken together, the above results suggest that instead of oral delivery, vaginal delivery may be beneficial in attenuating deleterious effects of NO by reducing the concentration of NO.

A significant decrease in TBARs levels of aorta (36.86 ± 3.88 nmol/g tissue) and salivary gland tissues (322.72 ± 43.17 nmol/g tissue) was observed in the vaginal delivery groups when compared with oral delivery groups (131.41 ± 16.66 nmol/g tissue, 749.15 ± 67.50 nmol/g tissue, respectively) ($p < 0.05$) (Figure 1). Lipid peroxidation products are markers for oxidative stress status *in vivo* and its related diseases. Malondialdehyde (MDA) is an important oxidation product, which is considered as the main marker in lipid peroxidation, and can be measured via TBARs assay [28–30]. Some metabolites are formed by the metabolism of oxybutynin by the cytochrome P450 enzyme system. One of these, *N*-desethyloxybutynin, is a stable and toxic metabolite [31]. This oxybutynin derived toxic metabolite can alter

oxidative stability. Oxidative stress may lead to dysfunction of salivary gland [32]. Several studies have shown oxidative stress effects secretion and components (calcium, protein, etc.) of saliva [33, 34]. Additionally, it has been suggested that ROS concerned with the onset and pathology of SS [15, 34, 35]. Similarly to salivation, heart failure may also be associated with oxidative stress. Studies of the causes responsible for the progression of heart failure have shown that reactive oxygen species (ROS) play an important pathological role [36]. Overall, these findings indicate that vaginal delivery may be beneficial as it reduces TBARS levels and hence oxidative stress.

In all tissue samples, the level of GSH in the oral delivery group (aorta ($5.83 \pm 0.67 \mu\text{mol/g}$ tissue), salivary gland ($19.72 \pm 3.45 \mu\text{mol/g}$ tissue), and small intestine ($5.95 \pm 0.56 \mu\text{mol/g}$ tissue)) was found to be higher than vaginal delivery group ($2.98 \pm 0.23 \mu\text{mol/g}$ tissue, $13.77 \pm 3.97 \mu\text{mol/g}$ tissue, $3.86 \pm 0.48 \mu\text{mol/g}$ tissue, respectively), but it was not statistically significant ($p > 0.05$) (Figure 1). GSH is a tripeptide acts as a free radical scavenger and is an important member of antioxidant defense system. The reason for this is not clear, but a possible explanation may be that the organism may have increased the level of GSH in order to strengthen the antioxidant defense system in response to increasing oxidative stress (parallel with TBARS result).

4. Conclusion

Oxidants, especially nitric oxide, play an important role in the pathophysiology of many diseases. Instead of orally administration, vaginal administration of oxybutynin can alleviate oxidant-induced side effects. These results can contribute to pharmaceutical studies.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Conflicts of Interest

The authors state no conflict of interest.

References

- [1] R. Vozmediano-Chicharro, B. Madurga, and P. Blasco, "Efficacy of transdermal oxybutynin in the treatment of overactive bladder syndrome: does it make sense using it in 2017?," *Advances in Urology*, vol. 2018, Article ID 6782736, 7 pages, 2018.
- [2] F. Tuğcu-Demiröz, F. Acartürk, and D. Erdoğan, "Development of long-acting bioadhesive vaginal gels of oxybutynin: formulation, in vitro and in vivo evaluations," *International Journal of Pharmaceutics*, vol. 457, no. 1, pp. 25–39, 2013.
- [3] R. Eapen and S. Radomski, "Review of the epidemiology of overactive bladder," *Research and Reports in Urology*, vol. 2016, pp. 71–76, 2016.
- [4] K. S. Coyne, C. C. Sexton, V. Vats, C. Thompson, Z. S. Kopp, and I. Milsom, "National community prevalence of overactive bladder in the United States stratified by sex and age," *Urology*, vol. 77, no. 5, pp. 1081–1087, 2011.
- [5] Y. C. Chuang, S. P. Liu, K. S. Lee et al., "Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study," *Lower Urinary Tract Symptoms*, pp. 1–8, 2017.
- [6] V. Hopkinson and I. Pearce, "Pharmacotherapy in overactive bladder," *Journal of Clinical Urology*, vol. 11, no. 1, pp. 38–47, 2017.
- [7] P. Abrams and K.-E. Andersson, "Muscarinic receptor antagonists for overactive bladder," *BJU International*, vol. 100, no. 5, pp. 987–1006, 2007.
- [8] J. Jayarajan and S. B. Radomski, "Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life," *Research and Reports in Urology*, vol. 6, pp. 1–16, 2014.
- [9] A. Athanasopoulos and K. Giannitsas, "An overview of the clinical use of antimuscarinics in the treatment of overactive bladder," *Advances in Urology*, vol. 2011, Article ID 820816, 8 pages, 2011.
- [10] J. I. Ivanova, E. Hayes-Larson, R. A. Sorg, H. G. Birnbaum, and T. Berner, "Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on antimuscarinic therapy for overactive bladder," *Journal of Medical Economics*, vol. 17, no. 10, pp. 741–750, 2014.
- [11] J. A. Cohn, E. T. Brown, W. S. Reynolds, M. R. Kaufman, D. F. Milam, and R. R. Dmochowski, "An update on the use of transdermal oxybutynin in the management of overactive bladder disorder," *Therapeutic Advances in Urology*, vol. 8, no. 2, pp. 83–90, 2016.
- [12] V. Kumar, A. A. Khan, A. Tripathi et al., "Role of oxidative stress in various diseases: relevance of dietary antioxidants," *Journal of Phytopharmacology*, vol. 4, no. 2, pp. 126–132, 2015.
- [13] A. Phaniendra, D. B. Jestadi, and L. Periyasamy, "Free radicals: properties, sources, targets, and their implication in various diseases," *Indian Journal of Clinical Biochemistry*, vol. 30, no. 1, pp. 11–26, 2014.
- [14] E. Birben, U. M. Sahiner, C. Sackesen, S. Erzurum, and O. Kalayci, "Oxidative stress and antioxidant defense," *World Allergy Organization Journal*, vol. 5, no. 1, pp. 9–19, 2012.
- [15] K. Ryo, A. Takahashi, Y. Tamaki, M. Ohnishi-Kameyama, H. Inoue, and I. Saito, "Therapeutic effects of isoflavones on impaired salivary secretion," *Journal of Clinical Biochemistry and Nutrition*, vol. 55, no. 3, pp. 168–173, 2014.
- [16] Y. Yamauchi, T. Matsuno, K. Omata, and T. Satoh, "Relationship between hyposalivation and oxidative stress in aging mice," *Journal of Clinical Biochemistry and Nutrition*, vol. 61, no. 1, pp. 40–46, 2017.
- [17] M. L. Breseghelo, L. A. Guillo, T. E. Nogueira et al., "Nitric oxide concentration and other salivary changes after insertion of new complete dentures in edentulous subjects," *International Journal of Dentistry*, vol. 2016, Article ID 8351427, 6 pages, 2016.
- [18] B. Dindar, K. Kaltalioglu, and S. Coskun-Cevher, "Effect of dual growth factor administration on oxidative markers during acute stage wound healing in rats," *Turkish Journal of Zoology*, vol. 41, pp. 841–847, 2017.
- [19] P. Domingos, A. M. Prado, A. Wong, C. Gehring, and J. A. Feijo, "Nitric oxide: a multitasked signaling gas in plants," *Molecular Plant*, vol. 8, no. 4, pp. 506–520, 2015.

- [20] P. Gul, H. Alp, A. Kiziltunc, and N. Akgul, "Effects of composite restorations on nitric oxide and uric acid levels in saliva," *Contemporary Clinical Dentistry*, vol. 6, no. 3, pp. 381–385, 2015.
- [21] G. B. Proctor and G. H. Carpenter, "Salivary secretion: mechanism and neural regulation," in *Saliva: Secretion and Functions*, A. J. M. Ligtenberg and E. C. I. Veerman, Eds., vol. 24, pp. 14–29, 2014.
- [22] J. Malone, "Inflammation, nitric oxide and Sjögren's syndrome," *British Sjögren' Syndrome Association Today Magazine*, vol. 25, no. 2, pp. 2-3, 2010.
- [23] Y. T. Kontinen, L. A. M. Platts, S. Tuominen et al., "Role of nitric oxide in Sjögren's syndrome," *Arthritis and Rheumatism*, vol. 40, no. 5, pp. 875–883, 1997.
- [24] G. Özcan, E. A. Şahin, and E. Demirel Yilmaz, "Effect of nitric oxide on cardiac functions: review," *Turkiye Klinikleri Cardiovascular Sciences*, vol. 28, no. 3, pp. 99–117, 2016.
- [25] A. Gamboa, L. E. Okamoto, S. R. Raj et al., "Nitric oxide and regulation of heart rate in patients with postural tachycardia syndrome and healthy subjects," *Hypertension*, vol. 61, no. 2, pp. 376–381, 2013.
- [26] X. Wang, Y.-X. Zhong, Z.-Y. Zhang et al., "Effect of L-NAME on nitric oxide and gastrointestinal motility alterations in cirrhotic rats," *World Journal of Gastroenterology*, vol. 8, no. 2, pp. 328–332, 2002.
- [27] R. Tomita, S. Fujisaki, T. Ikeda, and M. Fukuzawa, "Role of nitric oxide in the colon of patients with slow-transit constipation," *Diseases of the Colon and Rectum*, vol. 45, no. 5, pp. 593–600, 2002.
- [28] E. Niki, "Lipid peroxidation products as oxidative stress biomarkers," *BioFactors*, vol. 34, no. 2, pp. 171–180, 2008.
- [29] T. M. Potter, B. W. Neun, and S. T. Stern, "Assay to detect lipid peroxidation upon exposure to nanoparticles," *Methods in Molecular Biology*, vol. 697, pp. 181–189, 2010.
- [30] A. Zeb and F. Ullah, "A simple spectrophotometric method for the determination of thiobarbituric acid reactive substances in fried fast foods," *Journal of Analytical Methods in Chemistry*, vol. 2016, Article ID 9412767, 5 pages, 2016.
- [31] R. K. Malcolm, S. D. McCullagh, and R. J. Morrow, "Vagina and uterus as drug-absorbing organs," in *Enhancement in Drug Delivery*, E. Touitou and B. W. Barry, Eds., vol. 1, p. 429, 2006.
- [32] M. Choromańska, A. Klimiuk, P. Kostecka-Sochoń et al., "Antioxidant defence, oxidative stress and oxidative damage in saliva, plasma and erythrocytes of dementia patients. Can salivary AGE be a marker of dementia?," *International Journal of Molecular Sciences*, vol. 18, no. 10, p. 2205, 2017.
- [33] M. Pande and S. J. S. Flora, "Lead induced oxidative damage and its response to combined administration of α -lipoic acid and succimers in rats," *Toxicology*, vol. 177, no. 2-3, pp. 187–196, 2002.
- [34] T. Yamada, K. Ryo, Y. Tai et al., "Evaluation of therapeutic effects of astaxanthin on impairments in salivary secretion," *Journal of Clinical Biochemistry and Nutrition*, vol. 47, no. 2, pp. 130–137, 2010.
- [35] K. Okabayashi, T. Narita, Y. Takahashi et al., "Effect of oxidative stress on secretory function in salivary gland cells," in *Oxidative Stress-Environmental Induction and Dietary Anti-oxidants*, V. Lushchak, Ed., pp. 189–200, 2012.
- [36] H. Nojiri, T. Shimizu, M. Funakoshi et al., "Oxidative stress causes heart failure with impaired mitochondrial respiration," *Journal of Biological Chemistry*, vol. 281, no. 44, pp. 33789–33801, 2006.